Hepatic Energy Transduction Reverse Electron Transport, Mechanical Lock-In, and the Horizon of Reversibility

The companion monograph on type 2 diabetes treated chronic disease as a sustained reduction in the system’s capacity to acquire usable energy. The present work opens that reduction and examines its interior in the liver. What appears, under sustained substrate load, is not a fixed deficit but an oscillating supply state governed by the mitochondrial nicotinamide pool, replenished on a circadian schedule and consumed by the oxidative consequences of feeding. When daily substrate load is held constant and only the timing of intake is changed, the consequences are large. Mean energetic strain rises modestly, peak membrane stress rises sharply, and the load at which the liver loses a healthy operating state falls by a factor of several-fold between a morning and a nocturnal feeding window. An account based only on daily averages captures the smaller shift and misses the decisive loss of stability. From this breach the architecture of advanced disease follows. Late hepatic disease is treated not as a worse version of early disease, but as a differently maintained state, sustained by metabolic, mechanical, and systemic loops acting on different scales. The late state is bistable: once established, fibrotic maintenance can persist even when the original metabolic drive is reduced. At the same time, the model exposes its own failures with equal clarity. Under default assumptions, established fibrosis does not regress; genuine regression thresholds appear only in a narrow region of weakened mechanical lock-in; and the systemic loop, though architecturally important, shifts thresholds only modestly in computation. The monograph states its costs in advance: a high-dimensional module, a distributed delay, and many weakly anchored parameters. Its central empirical claim is simple and still untested in the required form — that progression and regression thresholds differ when measured on a common control parameter in the same hepatic cohort.